Dmitriy Feldman, MD
Interventional Cardiology · New York, NYNPI 1568632859
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (33.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 71.9% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $15,550, 2.5 times the $6,271 reported in 2019.
Across 191 payments — averaging $158.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$22K
- Novartis$2K
- Abbott$2K
- Boston Scientific$881
- W. L. Gore & Associates, Inc.$600
- Philips North America LLC$531
- plus $2K from 13 others
Across 42 payments — averaging $8811.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$292K
- Janssen Research & Development, LLC$78K
What the payments were for
- Consulting fees$9,66432%
- Speaking & faculty fees$7002%
- Travel & lodging$9,74932%
- Food & beverage$10,12433%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 101 | $21,733 |
| Novartis | 2 | $2,498 |
| Abbott | 46 | $2,035 |
| Boston Scientific | 10 | $881 |
| W. L. Gore & Associates, Inc. | 1 | $600 |
| Philips North America LLC | 5 | $531 |
| Shockwave Medical, Inc | 4 | $518 |
| Spectrawave, Inc | 5 | $398 |
| Abiomed | 2 | $265 |
| Endologix LLC | 2 | $206 |
| Edwards Lifesciences | 1 | $145 |
| United Therapeutics Corporation | 1 | $100 |
| Atricure, Inc. | 2 | $81 |
| Teleflex LLC | 1 | $64 |
| Amgen | 3 | $62 |
| Chiesi USA, Inc. | 2 | $34 |
| AstraZeneca | 1 | $33 |
| Cardiva Medical, Inc. | 1 | $28 |
| Scpharmaceuticals Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$11,489
- Resolute$4,733
- LEQVIO$2,498
- Product in Development$600
- Xience Sierra Coronary Stent System$483
- Abre$458
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$443
- IGT D Serv Und$332
- COROFLOW$320
- Impella$265
- HyperVue Imaging System$192
- Starlight Imaging Catheter$192
- CoreValve Evolut$180
- ROTAPRO$174
- AVVIGO Guidance System$172
- COREVALVE EVOLUT R$170
- Torus Stent Graft System$150
- ENDOCROSS Device$150
- (6399) Angio iFR$148
- SAPIEN 3 Ultra RESILIA$145
How this compares
$30,237 in reported general payments places this provider in the 70th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $38,454 |
| BrilintaTicagrelor | 29 | $28,089 |
| Ezetimibe | 122 | $3,041 |
| Rosuvastatin Calcium | 135 | $2,178 |
| Metoprolol Succinate | 98 | $1,586 |
| Atorvastatin Calcium | 127 | $1,424 |
| ClopidogrelClopidogrel Bisulfate | 91 | $862 |
| Amlodipine Besylate | 90 | $778 |
| Omega-3 Acid Ethyl Esters | 14 | $628 |
| Losartan Potassium | 61 | $541 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 37 | $515 |
| Spironolactone | 22 | $345 |
| Carvedilol | 32 | $233 |
| Enalapril Maleate | 14 | $195 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 16 | $180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $33 | $28,08929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in New York
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- Prakash KrishnanNew York$387K
- Jaikirshan KhatriNew York$307K
- Samin SharmaNew York$291K
- Torsten VahlNew York$280K
- George DangasNew York$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.